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Background: Neurofeedback has been applied effectively in various areas, especially in the treatment of children
with attention-deficit/hyperactivity disorder (ADHD). This study protocol is designed to investigate the effect of slow
cortical potential (SCP) feedback and a new form of neurofeedback using near-infrared spectroscopy (NIRS) on
symptomatology and neurophysiological parameters in an adult ADHD population. A comparison of SCP and NIRS
feedback therapy methods has not been previously conducted and may yield valuable findings about alternative
treatments for adult ADHD.
Methods/Design: The outcome of both neurofeedback techniques will be assessed over 30 treatment sessions and
after a 6-month follow-up period, and then will be compared to a nonspecific biofeedback treatment. Furthermore,
to investigate if treatment effects in this proof-of-principle study can be predicted by specific neurophysiological
baseline parameters, regression models will be applied. Finally, a comparison with healthy controls will be conducted
to evaluate deviant pretraining neurophysiological parameters, stability of assessment measures, and treatment outcome.
Discussion: To date, an investigation and comparison of SCP and NIRS feedback training to an active control has not
been conducted; therefore, we hope to gain valuable insights in effects and differences of these types of treatment for
ADHD in adults.
Trial registration: This study is registered with the German Registry of Clinical Trials: DRKS00006767, date of registration:
8 October 2014.
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Attention-deficit/hyperactivity disorder (ADHD) is one
of the most common disorders of childhood with a cu-
mulative incidence of up to 7.5% by 19 years of age [1].
The primary symptoms of ADHD include inattentive-
ness, impulsivity, and hyperactivity, which persist into
adulthood for a large proportion of children diagnosed
with this disorder. The estimated prevalence of clinician-
assessed adult ADHD in general and clinical populations* Correspondence: kerstin.mayer@uni-tuebingen.de
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unless otherwise stated.is 4 to 5% and 7.5%, respectively [2,3]. Impairments in
educational, occupational, neuropsychological and social
functioning are observed [4]. Psychiatric comorbidities are
highly prevalent in the adult ADHD population and in-
clude mood, anxiety, and substance abuse disorders [5].
Various findings indicate that ADHD has its origin in
neurobiological dysfunctions including a major genetic
component in etiology [6,7], specifically in relation to
the regulation of the dopaminergic neurotransmission
[8]. Relative to controls, ADHD adults have a significant
reduction in orbitofrontal volumes in the left hemi-
sphere [9], overall cortical gray matter reduction in pre-
frontal and anterior cingulum cortices [10] and volume
reductions in the cerebellum [11]. On a functional level,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sumed to underlie many of the deficits observed in
ADHD, with particular involvement of the dorsolateral
prefrontal cortex (DLPFC) and cingulate areas (for ex-
ample, [12]). Electroencephalography (EEG) studies
comparing adult individuals with ADHD to healthy con-
trols have identified a variety of brain activity patterns
including increased theta/beta ratios [13,14], increased
theta and alpha activity [15,16], and deviant activity in
delta and beta frequencies [17]. However, brain activity
patterns seem to be dependent on the ADHD subtype
[18]. Event-related potentials (ERP) also differ between
adult ADHD and healthy control populations, with adult
ADHD patients showing enhanced N100 and N200 and
decreased P300 activity [19,20] together with topo-
graphic differences in P100 and P200 [21] and P300
[22]. Additionally, altered error potentials indicate defi-
cits in conflict monitoring [23]. Rockstroh et al. [24] ob-
served impaired regulation of slow cortical potentials
(SCP), a specific type of ERP in which slow direct
current shifts reflect the excitation threshold of large
cortical cell assemblies in children with attention prob-
lems. SCP shifts in the electrically negative direction re-
flect a reduction of the excitation threshold, whereas
shifts in the electrical positive direction reflect an in-
crease of the excitation threshold. These studies show
the suitability of EEG/ERP recordings for measuring cor-
tical dysregulation during resting and task conditions for
participants with ADHD.
Looking at corresponding neuropsychological con-
cepts, ADHD has repeatedly been associated with a dis-
turbance of single or multiple executive functions such
as selective and divided attention and working memory.
Consequently, there have been various attempts to de-
termine intermediate phenotype markers based on mea-
sures grounded in neuroscience [25-27]. In spite of
considerable differences between the various intermedi-
ate phenotype models, deficits in executive functioning
have been demonstrated in most of them and have re-
peatedly been suggested to underlie the disease (for ex-
ample, [28]). Specifically, deficits in working memory,
response inhibition, and cognitive response control have
been identified in both ADHD participants and their un-
affected relatives, and have therefore been suggested as
cognitive intermediate phenotypes of ADHD [25,29,30].
A method optimally suited to assess the cortical aspect
of these deficits is near-infrared spectroscopy (NIRS), an
optical imaging method, which allows for noninvasive
in vivo measurements of changes in the concentration of
oxygenated (O2Hb) and deoxygenated (HHb) hemoglobin
in brain tissue [31-33]. NIRS has repeatedly been cross-
validated using, for example, blood-oxygen-level dependent
(BOLD) and arterial spin labeling-based functional mag-
netic resonance imaging (fMRI) [34,35], confirming thephysiological basis of the signal. In a NIRS study, poorer
performance in a working memory task was observed for
adult participants suffering from ADHD compared to
healthy controls [36]. The tendency for more omission er-
rors during a 2-back task was also associated with signifi-
cantly reduced prefrontal activation in the ADHD group
compared to healthy controls. Using another executive
control task, prefrontal deficits in adult ADHD participants
were again observed, even when no overt performance dif-
ferences occurred [37]. These studies show the suitability
of NIRS in measuring prefrontal control deficits during
tasks of executive function in participants with ADHD.
In neurofeedback treatment, participants learn to
regulate their own brain activity (for example, SCP, EEG
oscillations, O2Hb concentration, etcetera) using online
feedback. The training is based on an operant condition-
ing process in which only the desired brain activity is
rewarded. As stated previously, Rockstroh et al. [24] ob-
served impaired regulation of SCP and reduced negativ-
ities in anticipation of a task in children with attentional
problems. Helps et al. [38] found that ADHD children
exhibited decreased resting state very low frequency
power (0.1 Hz) and attenuated power during rest-task
transitions that varied significantly from healthy con-
trols. Attenuation of power was negatively correlated
with task performance, whereby participants who atten-
uated least made more errors, had greater variability,
and slower reaction times (RT). These findings support
the conceptualization of ADHD symptoms as impaired
excitation threshold regulation, characterized by decreased
cortical negativity. Therefore, it was hypothesized that
training ADHD participants to augment negative SCP
would increase the capacity to produce cortical activation
necessary for concentration and cognitive tasks.
The use of SCP as a treatment parameter for children
with ADHD has yielded significant reduction in ADHD
symptoms, improved attention [39-41], and has pro-
duced changes in ERP, most importantly for SCP feed-
back of the contingent negative variation (CNV) (for
example, [40,42]). A recent study by Studer et al. [43]
with healthy adult participants found increased CNV
amplitude after SCP feedback training. Examination of
EEG during SCP-treatment indicated that children with
ADHD are able to control SCPs and this skill was ob-
served to be stable two years after the end of treatment
[44]. Therefore, one of the potential advantages of neu-
rofeedback therapy over pharmacological treatment
strategies might be the stability of improvements beyond
the intervention period. As this has been shown to be an
effective treatment for children, we would like to investi-
gate whether SCP feedback is an efficient treatment for
adult ADHD participants as well.
In recent years, some efforts have been made to extend
neurofeedback applications from the electrophysiological
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methods such as fMRI have the advantage of a superior
spatial resolution (compared to EEG), theoretically allow-
ing for neurofeedback training of circumscribed brain
areas. Investigation of fMRI feedback has subsequently
shown that healthy adult subjects are able to quickly learn
to self-regulate brain activity on the basis of the BOLD sig-
nal [45-47]. As NIRS and fMRI both measure the regula-
tion of the blood metabolism, we expect similar findings
with NIRS feedback. As NIRS is relatively insensitive to
motion artifacts and allows measurements to be performed
in a natural, relaxed sitting position, it might provide an
interesting alternative to fMRI for feedback training in
psychiatric disorders such as ADHD. To date, only a few
studies have attempted to use functional near-infrared spec-
troscopy (fNIRS) with a neurofeedback protocol [48]. In a
pilot project, real-time feedback was provided to train sub-
jects to increase their motor cortex activation using motor
imagery. It was shown that the signal-to-noise ratio of the
O2Hb signal increased significantly over the course of the
feedback training within five sessions. In another study, 21
subjects performed motor imagery with relevant cortical
feedback and sham feedback. Only in the “verum” feedback
condition has greater activation of the contralateral pre-
motor cortex been induced [49].
Based on this preliminary work, we want to investigate
the efficacy and long-term stability of fNIRS feedback in
comparison with EEG feedback.
Additionally, neurophysiological predictors of treat-
ment outcome will be investigated. Target parameters of
the baseline NIRS and EEG assessments will be used as
predictors in regression analyses. Based on previous
findings regarding the prediction of treatment outcome
via EEG markers of frontal lobe function in schizo-
phrenic patients [50], we expect treatment effects to be
particularly pronounced in participants with weak acti-
vation in the baseline frontal lobe assessments, especially
for the NIRS feedback arm that is specifically focused on
strengthening frontal lobe function. Regarding the EEG
baseline data, mean relative theta and relative beta
power as well as theta/beta ratios will be calculated for
frontal and central regions of interest (ROI) during the
eyes open and eyes closed resting state conditions. Add-
itionally, P300 and CNV amplitudes and latencies will be
calculated during neuropsychological assessment. Re-
search indicates that adult ADHD participants possess
elevated theta/beta ratios [13,14], which have been found
to discriminate ADHD participants from healthy control
populations [51,52]. These ratios may have prognostic
value for prediction of outcome after stimulant medication
as well as after neurofeedback treatment [18]. Elevated
theta/beta ratios are hypothesized to reflect task-related
brain “activation” and serve as a discriminant of behavioral
performance [53]. Dominant slow wave activity has beenlinked with reduced auditory oddball P300 activity [54]
and stimulant medication response [52], while larger pre-
training CNV activation has been linked with larger symp-
tom reductions following SCP feedback [55]. Therefore, we
expect effects to be particularly pronounced in participants
with elevated theta/beta ratios and decreased P300 ampli-
tude but greater CNV negativity at baseline assessment.
Methods/Design
In this proof-of-principle study, a total of 60 adult partici-
pants diagnosed with ADHD (combined, hyperactive, or in-
attentive type) are randomly blockwise assigned to SCP,
NIRS, or electromyogram (EMG) feedback groups (n = 20
each) stratified for age, sex, and educational level. This is
the first study to investigate and compare the efficacy of
these treatment modalities in an adult ADHD population.
Twenty healthy controls matched for age, sex, IQ, and
pre- and post-treatment duration will be included in the
neurophysiological assessments for pre- and post-treatment
measurement in order to establish “expected” activation
patterns and allow for a more thorough interpretation of
changes following the neurofeedback treatment. The study
objectives are as follows:
1. Assess whether there are physiological differences
(EEG and ERP) in ADHD participants compared to
healthy controls.
2. Assess whether adult participants are able to
demonstrate learning of cortical self-regulation.
3. Assess whether treatment leads to an improvement
in cognition (that is, attention and working memory)
and behavior (that is, restlessness and impulsivity),
and changes in specific EEG or NIRS parameters.
4. Assess whether specific methods and protocols are
more efficacious in changing behavioral, cognitive,
and EEG and NIRS outcome variables.
5. Assess whether changes are stable at the 6-month
follow-up.
6. Assess whether specific methods and protocols differ
in the stability of cortical self-regulation and clinical
effects at the 6-month follow-up.
7. Assess whether the efficiency of the different
training protocols differs depending on individual
neurocognitive baseline parameters (for example,
frontal lobe activation during neuropsychological
assessments; baseline CNV etc.).
Study flow
At baseline/pre-treatment, participants are screened and
diagnosed with ADHD, assessed with a battery of neuro-
psychological questionnaires for evaluation of cognitive
and behavioral outcome variables, and evaluated using a
22-channel NeXus-32 (Mind Media B.V. with Biotrace+
Software, Herten, The Netherlands) continuous EEG
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auditory Go/NoGo task). Moreover, concentration changes
of O2Hb and HHb during three executive functioning tasks
(working memory, Go/NoGo, and word fluency) are mea-
sured by a 52-channel continuous wave NIRS-system
(ETG-4000, Hitachi Medical Co., Tokyo, Japan). At mid-
treatment (that is, after 15 sessions), post-treatment (after
30 sessions), and 6-month follow-up, the neuropsycho-
logical assessments are repeated.
Healthy controls (n = 20) undergo the EEG/NIRS assess-
ment for the pre- and post-treatment measurement points.
See Figure 1 for an illustrated overview of the study flow.
Participants and recruitment
Participants of the ADHD group, as well as the healthy
control group, are being recruited from the University ofFigure 1 Study flow of assessments and treatment for the attention-deficit hypTübingen student population, and non-student adults
are being recruited through university mailing lists and
by flyer. We are including all occupations and academic
levels to have a diverse sample. The initial screening is
conducted via phone and questionnaires are being
mailed to check for the inclusion criteria. With the
mailed questionnaires, potential participants also receive
detailed information material and the informed consent
form. The ADHD diagnostic assessment is scheduled if
inclusion criteria are met. The control participants are
being selected for age and sex and are included after the
IQ test reveals them as a match for a patient.
Ethics and written consent
This study (DRKS00006767) was approved by the local
Ethics Committee (Ethics Committee for the Medicaleractivity disorder (ADHD) groups (in white) and the control group (in gray).
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votum number: 434/2010B01; Date 15 October 2012) ac-
cording to the Declaration of Helsinki. Before entering the
study, participants are informed about the study objec-
tives, study design, and potential risks by one of the main
investigators and are given this information in writing.
Written consent is obtained from all participants.
Study-related information and informed consent is ad-
ministered by the investigator(s) to ensure that partici-
pant questions and concerns are addressed. Participants
receive the following information designed to educate
him/her extensively on the subject of the investigation:
information regarding the overall study; information on
the goals, methods, and procedures of the study; and the
end of the study plan. Participants are informed that
they have the right to discontinue their participation at
any time without giving a specific reason and without
penalty.Inclusion and exclusion criteria
Participants include adults 18 years and older who meet
the following inclusion criteria (please see “Assessments”
section below for an explanation of all abbreviations):Table 1 List of all assessments and their respective time of ac
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ADHD-SB, ADHS-Selbstbeurteilungsskala (German ADHD self-rating scale); BDI-II, Beck’s Dep
CFT-20-R, Culture Fair Test-20 Revised; d2-R, Test of Attention; FEA-FFB and FEA-AFB, Frage
Fremdbeurteilung (German ADHD third-party rating scale); FERT, Fragebogen zur Erfassun
SCID, Structured Clinical Interview for DSM-IV Disorders; WRI, Wender-Reimherr Interview; W
EHI, Edinburgh Handedness Inventory; PPI, Psychopathic Personality Inventory; Q, question1. Attention Deficit Disorder inattentive type or
hyperactive type or combined type according to
DSM-IV criteria (ADHS-SB ≥18; WURS-K ≥30;
WRI = adult ADHD).
2. No additional serious physical, neurological, or
psychiatric disorders with the exception of moderate
depression (BDI-II score <28) and personality
disorders, however, antisocial (SCID-II) or borderline
personality disorders (BSL-23 ≤ 47) were excluded.
3. Full scale IQ >80.
Participants are excluded based on the following:
1. Self-reported diagnosis of the following current
symptoms: Serious physical illness or chronic
diseases such as lung disease, heart disease, diabetes,
hypertension, and rheumatic diseases; neurological
disorders including Parkinson’s disease, stroke,
multiple sclerosis and epilepsy; or indicated
psychiatric disorders including bipolar disorder,
psychosis, obsessive-compulsive disorder, chronic
tics, Tourette syndrome, and suicidal behavior.
2. Previous participation in another neurofeedback study.quisition















ression Inventory; BSL-23, Borderline Symptom List; STAI, State Trait Anxiety Inventory;
bogen zur Erfassung von ADHS im Erwachsenenalter, frühere/aktuelle Probleme -
g relevanter Therapiebedingungen (German therapy effect rating scale); FU, Follw-up;
URS-K, Wender Utah Rating Scale; PANAS, Positive Affect Negative Affect Schedule;
naire; EEG, electroencephalography; NIRS, near-infrared spectroscopy.
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tionnaires are mailed to check for the inclusion criteria.
The ADHD diagnostic assessment (see Table 1) will be
scheduled if inclusion criteria are met. If the participants
are on medications such as any short-acting stimulants,
they are asked not to take them for at least 24 h prior to
each assessment. For the neurofeedback treatment period,
they may take their medication but on a stable dose. We
do not stratify randomization for medication as we expect
the usage to be very diverse.
Interventions
Slow cortical potential feedback
SCP feedback is conducted with the THERAPRAX (neu-
roConn GmbH, Ilmenau, Germany). The feedback proto-
col was developed by researchers at the Institute for
Medical Psychology and Behavioral Neurobiology and has
been used for many years in a variety of studies [56]. SCP
are recorded at Cz referenced against mastoid A1 with a
ground electrode on mastoid A2. Each SCP session con-
sists of four runs of 40 trials, with each trial lasting 8 s and
consisting of three phases: a baseline phase (seconds 0 to
2), an active phase (seconds 2 to 10), and a reinforcement
phase (seconds 10 to 12) (See Figure 2). At the end of the
baseline phase, participants are cued by a triangle directed
to the top of the screen to “activate” their brain and by a
triangle directed to the bottom of the screen to “deacti-
vate” their brain. “Activation” in the SCP group means to
produce an SCP shift in the electrically negative direction.
“Deactivation” means to produce an SCP shift in the elec-
trically positive direction. In all sessions, trials with re-
quired activation and deactivation will be randomly
distributed and make up 50% of all trials.
Participants are trained one to three times per week
(maximum of five times per week) for a total of 30 ses-
sions. Each session lasts about an hour, including the
preparation time and is divided into four 8-min blocks.
To generalize newly acquired regulation skills to every-
day life situations, the third block in each session serves
as “transfer block” in which no visual feedback is pre-
sented during the active feedback phase of each trial.
The level of success is indicated with the visual reward
system only. Participants are instructed to use their self-Figure 2 Neurofeedback trial set-up: 2sec baseline, 8sec active phase andregulation in everyday life situations. After the 15th ses-
sion, participants are provided with a 15 × 5 inch picture
of the neurofeedback screen as a memory aid as well as
a CD playing a video of the transfer trials without feed-
back to help the transfer to daily life.
Near-infrared spectroscopy feedback
The extent of prefrontal activation in terms of changes in
O2Hb concentration is displayed online on a computer
screen. Based on previous fMRI feedback protocols and
the SCP-feedback screen described above, participants are
instructed via visual commands (triangle on the screen) to
regulate PFC activity up (“activation period”) or down
(“deactivation period”). During the activation period, up-
regulation of PFC activity is operationalized as an increase
in the concentration of O2Hb within a predefined region
of interest (NIRS channels covering left and right lateral
prefrontal areas). During the deactivation period, on the
other hand, participants should achieve a decrease in
O2Hb concentration within the same target region. Func-
tionally, such a decrease in prefrontal oxygenation below
baseline levels will probably be associated with an in-
creased blood supply in other parts of the brain, for ex-
ample, visual association areas or parts of the default
network. In between each “active” period (activation versus
deactivation), rest trials ensure a return of hemodynamic
activation to baseline levels. One session consists of a total
of 24 activation periods (30 s each), separated by 30-s rest-
ing periods. Also in accordance with the SCP feedback
protocol (see above), the ratio of “activation” to “deactiva-
tion periods” is 50/50 over the course of all sessions.
Moreover, a block of eight “transfer trials” will be included
after the first block of 12 activation trials. Participants will
be trained one to three times per week for a total of 30 ses-
sions. Each session lasts about 40 minutes, including prep-
aration time.
Electromyogram feedback
For the EMG feedback, an EMG biofeedback application
is used based on the protocol being already used in the
above-mentioned clinical study “Neurofeedback in chil-
dren with ADHD” (Ho 2503 4/1) [57]. EMG electrodes2sec reinforcement phase.
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tus. In addition, EEG electrodes are placed onto the
scalp to imitate an EEG or NIRS recording. The relation
between relaxation on the left and tension of the right
muscle is used as the feedback signal when participants
are asked to regulate the signal up. To regulate it down,
the left muscle has to become tense while the right has
to be relaxed. Trial length, visual output, transfer trials
and overall duration resemble the SCP neurofeedback as
described above as closely as possible.
Preliminary data from the multicenter controlled ran-
domized study for children with ADHD [57] show su-
perior outcome for SCP compared to EMG. In another
pilot study, children with ADHD underwent NIRS feed-
back with comparable outcome after 12 sessions to SCP
feedback [58]. This is the first study to investigate adults,
and we use an identical design to rule out nonspecific ef-
fects. We compare two neurofeedback techniques (control
of metabolic and electrophysiological parameters) in their
effectiveness. In a second step we try to rule out nonspe-
cific effects by using a placebo-controlled training (EMG).
Expectancy effects are assessed with a questionnaire
(FERT - see below) and will be included in the analysis.Control group
The healthy controls undergo only part of the diagnostic
procedure, including the ADHD-SB, BDI, STAI, EHI,
BSL, d2, CFT-20-R (see section below for explanation),
demographic and medical history questionnaires, and
the EEG and NIRS assessment. The controls are assessed
at two time points but do not receive any treatment in
between. The first measurement is being performed dir-
ectly after the recruitment and screening procedure. The
time between the first and the second measurement is
dependent on the amount of time it takes the matched
patient to complete treatment (+/− two months).Randomization and blinding
The randomization is conducted in two steps: first a block-
wise randomization, and second a pairwise randomization
for age, sex and IQ. We determined a grouping order
(EEG = 1; NIRS = 2; and EMG= 3). If the participant does
not fit into group 1, he/she is matched to group 2 and if
not group 2, then group 3. For the next participant, the
matching process starts in group 2 and so forth.
The participants are not blinded to the treatment con-
dition, as it is easier to achieve physiological self-control
knowing which parameter has to be controlled. Further,
blinding was not possible, due to the different feedback
methods that made it obvious which treatment was be-
ing applied and received (for example, NIRS vs. EEG
measurement setup). The different methods are used in
different labs and with different technical requirements,and therefore, neither blinding of participants nor blind-
ing of assessors was possible.
Assessments
Psychometric assessments
Medical history questionnaire (screening) Participants
are asked to indicate the following: sex; age; handedness;
years of education; occupation; previous episodes of
head injury with loss of consciousness; current medica-
tion and dosage history; other substances currently being
taken; prior experience with EEG/NIRS; for female par-
ticipants, pregnancy and oral contraceptive information.
This questionnaire is used to identify inclusion and ex-
clusion criteria.
ADHS-Selbstbeurteilungsskala (ADHS-SB; screening
and evaluation of outcome) The ADHS-SB is a 22-
item sub-scale questionnaire of the “Homburger ADHS-
Skalen für Erwachsene” (HASE, [59]). The self-report
questionnaire assesses the current ADHD symptoms (ac-
cording to the 18 diagnostic criteria for ADHD listed in
the DSM-IV and ICD-10-R) on a 0 to 3 Likert-Scale.
This questionnaire is used to identify inclusion criteria
and treatment effects on ADHD symptoms over time.
Beck’s Depression Inventory (BDI-II) The BDI-II is a
10-minute self-reported questionnaire assessing depres-
sion symptoms during the previous two weeks [60]. This
questionnaire is used to determine inclusion and treat-
ment effects on comorbid symptoms of depression over
time.
Borderline Symptom Liste - Kurzform (BSL-23) The
BSL-23 is a 23-item self-report questionnaire used to as-
sess borderline personality disorder symptoms on a 0 to
4 Likert-Scale [61]. This questionnaire is used to deter-
mine inclusion and treatment effects on comorbid symp-
toms of borderline over time.
Culture Fair Test-20 Revised (CFT-20-R; screening and
follow-up) The CFT-20-R is a nonverbal intelligence test
[62]. This test is used to determine inclusion and treat-
ment effects over time.
Edinburgh Handedness Inventory (EHI; screening)
The Edinburgh Handedness Inventory is a self-rated ques-
tionnaire that assesses right or left hand dominance for
ten activities [63]. This inventory is used for assessments.
Fragebogen zur Erfassung von ADHS im Erwachsene-
nalter, aktuelle Probleme/frühere Probleme - Fremd-
beurteilung (FEA-AFB, FEA-FFB; screening and
evaluation of outcome) The FEA-AFB and FEA-FFB
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(FEA-AFB) as well as childhood (FEA-FFB) ADHD-related
problems and symptoms for adult participants completed
by a spouse, family member, close friend or employer [64].
These questionnaires are used to determine inclusion and
treatment effects on third-party rated ADHD symptoms
over time.
Fragebogen zur Erfassung relevanter Therapiebedin-
gungen (FERT; evaluation of outcome) The FERT is a
self-rated questionnaire to assess relevant treatment
conditions, patient expectations, and patient-therapist
interactions [65]. This questionnaire is used to assess
treatment expectation as a nonspecific variable.
Structured Clinical Interview for DSM-IV Disorders
(SCID-I; SCID-II; screening) The SCID is a semi-
structured interview for the assessment of DSM-IV dis-
orders [66]. This interview is used for inclusion and
exclusion criteria.
Test d2- Revision Aufmerksamkeits- und Konzentra-
tionsstest (d2-R; screening and evaluation of out-
come) The d2-R is a 10-minute assessment in which
participants cross out the target letter from a series of
similar letters [67]. The total number of items processed
minus errors indicates combined speed and accuracy
scores for attentional and inhibitory control. This test is
used to assess attention in comparison with healthy con-
trols and for treatment effects over time.
Wender-Reimherr Interview (WRI; screening and
evaluation of outcome) The WRI is the structured
interview of the sub-scale of the HASE [59]. The inter-
view investigates psychopathological characteristics of
adult ADHD. Responses are rated on a 0 to 2 Likert-
Scale. This interview is used to determine inclusion and
treatment effects on third-party rated ADHD symptoms
over time.
Wender Utah Rating Scale-Kurzform (WURS-K;
screening) The WURS-K is a 25-item sub-scale ques-
tionnaire of the HASE [59]. The questionnaire estab-
lishes a retrospective diagnosis of childhood ADHD
symptoms for adult ADHD evaluation using a 0 to 4
Likert scale. This questionnaire is used to identify inclu-
sion criteria.
Psychopathic Personality Inventory (PPI) The PPI-R
is a 26-item self-report measure of emotional detach-
ment using a 1 to 4 Likert-Scale [68]. This inventory is
used to identify inclusion criteria.Schlaffragebogen A The “Schlaffragebogen A” is a 23-
item self-rated questionnaire that assesses sleep quality
and behavior for the previous night of sleep [69]. This
questionnaire is used to assess the quality of sleep before
the EEG measurements.
State-Trait Anxiety Inventory (STAI) The STAI is a
self-rated 40-item questionnaire about temporary and
long-term anxiety with a range of four possible re-
sponses to each [70]. This questionnaire is used to iden-
tify inclusion criteria and treatment effects on comorbid
symptoms of anxiety over time.
Change of living conditions checklist Every fifth feed-
back session, the participants fill in a general checklist
about living conditions including changes in sleep,
mood, coffee, nicotine or drug intake and any major
changes in their lives. This checklist is to identify any
major changes over the course of training that might
lead to nonspecific treatment effects.
Neurophysiological parameters
All neurophysiological parameters are assessed for com-
parison to the healthy control group and to assess
changes over the course of treatment.
Quantitative EEG (QEEG) data are collected using 22
EEG channels positioned according to the international
10–20 system. Two channels of the NeXus-32 (Mind
Media B.V. with Biotrace+ Software, Herten, The
Netherlands) will be dedicated to detecting horizontal
eye movements and are attached 1.5 cm lateral to the
outer canthus of each eye. Two additional electrodes will
be used to detect vertical eye movements and are at-
tached 3 mm above the middle of the left eyebrow and
1.5 cm below the middle of the left lower eyelid. Study
tasks include an assessment of eyes closed and eyes open
resting state, auditory oddball, and auditory Go-NoGo
task. The resting state assessment will consist of an 8-
min alternating eye open (1 min)/eyes closed (1 min)
asymmetry task, 15-min eyes-closed recording, directly
followed by a 5-min eyes-open recording. We will
analyze absolute and relative power for the delta (1.5-
3.5 Hz), theta (3.5-7.5 Hz), alpha (7.5-12.5 Hz), and beta
(12.5-25 Hz) frequency bands and calculate asymmetry,
coherence, alpha peak frequency, EEG phenotype, and
EEG vigilance stage changes. The variables will be used to
assess differences between the adult ADHD and health
control participants at baseline, as well as the pre- and
post-training effects in the ADHD participants.
Auditory P300 task (Go/NoGo-oddball task)
An auditory oddball task with three different tones (see
[71]) is used to elicit P3a and P3b components to in-
vestigate inter alia attentional resources for stimulus
Mayer et al. Trials  (2015) 16:174 Page 9 of 14evaluation. Participants have to press a response button
whenever they hear the previously defined target tone
(N = 60, 1500 Hz) in a 10.5-min paradigm with additional
standard tone (N = 359, 1000 Hz) and a less frequent dis-
tractor tone (N = 60, white noise). The three stimuli are
presented in a pseudo-randomized order (presentation
time: 50 ms; interstimulus-interval: 1300 ms). P300 ampli-
tude and latency over central, frontal and parietal elec-
trodes will be calculated, as well as RT, RT variability and
error rates.
Auditory P300 task (oddball task)
An auditory oddball task with two different tones is used
to elicit the P300 component. Participants have to si-
lently count the deviant tone with their eyes closed. An
8.5 min paradigm with standard tone (N = 150, 1000 Hz)
and a deviant tone (N= 49, 1500 Hz) will be used. The two
stimuli are presented in a pseudo-randomized order (pres-
entation time: 50 ms; interstimulus-interval: 1300 ms). At
the end of the paradigm, the experimenter asks for the
count and takes note. P300 amplitude and latency over
central, frontal and parietal electrodes will be calculated.
Auditory Go/NoGo task
An auditory Go/NoGo task with three different tones is
used to assess cognitive preparation, attention, and im-
pulsivity by instructing participants to press a response
button whenever they hear a previously defined target
stimulus (S2target, N = 50, 2000 Hz) that follows a warn-
ing stimulus (S1, N = 200, 500 Hz) at a variable presenta-
tion interval within a 14-min paradigm. All three stimuli
are presented in S1-S2 or S1-S2target segments. Each tone
is presented for 50 ms; the duration of each segment
lasts 1800 ms. The segments are presented in a pseudo-
randomized order with an interstimulus-interval of 2000
to 2400 ms. The CNV amplitude over central and frontal
electrodes will be calculated as well as the RT, RT vari-
ability and error rate.
Measures of peripheral physiology
Electrocardiogram (ECG), skin conductance level (SCL)
and respiration measures are simultaneously and con-
tinuously recorded using the Nexus 32 system (Mind
Media B. V., Herten, The Netherlands). ECG electrodes
are placed on the participants’ chest (reference/ground
below right and left clavicle and the active electrode
below left-side ribcage) and used to assess heart rate and
heart rate variability measures. A Velcro-elastic respir-
ation band is placed around the participants’ waist or
chest, based on comfort and signal quality. Finally, the
SCL sensors are fixed to the participants’ nondominant
hand with Velcro-sensors. The peripheral data from
heart rate, respiration and SCL will be used to assess theperipheral arousal during active (ERP tasks) and resting
(eyes open/eyes closed) conditions.
NIRS acquisition
Functional near-infrared spectroscopy (fNIRS) is con-
ducted with the ETG-4000 Optical Topography System
(Hitachi Medical Co., Tokyo, Japan), a continuous wave
system working with two different wavelengths (695 ± 20
and 830 ± 20 nm) and a temporal resolution of 10 Hz.
Relative changes of absorbed near-infrared light are
transformed into concentration changes of O2Hb and
HHb by means of a modified Beer-Lambert law. Two
optode sets (each consisting of eight emitters and seven
detectors; interoptode distance: 30 mm) are placed over
left and right prefrontal regions (6 x 12 cm each). They
are orientated according to the standard EEG positions
F3, T3 and F4, and T4 [72,73].
Working memory task (n-back task)
A letter n-back task (see, for example, [36]) with three
different conditions is used to investigate functions of
working memory (WM). In the 0-back condition (mar-
ginal WM load), participants have to press a response
button whenever a previously defined target letter ap-
pears in a stream of different letters. In the 1-back con-
dition (low WM load), participants have to press the
response button whenever the letter appearing on the
computer screen is identical to the preceding letter. In
the 2-back condition (high WM load), participants have
to press the response button whenever the current letter
is identical to the letter presented two trials before.
These three conditions are performed alternately in a
blockwise fashion, separated by 30-s resting segments
during which participants are instructed to sit still and
relax. Letters are presented in pseudo-randomized order
with a presentation time of 300 ms and an interstimulus-
interval of 1700 ms, resulting in 30-s task segments. Each
of the three task conditions is conducted three times; that
is, participants perform nine task segments. Additionally,
a 10-s baseline period precedes the first task segment. For
all three conditions, a total of 12 target trials appear across
task segments. The button presses are recorded, and the
number of errors and correct responses, as well as the RT,
will be analyzed as behavioral data. The task lasts for
about 10 min.
Response inhibition task (Go-NoGo task)
A Go-NoGo task is used to investigate executive functions
in terms of response inhibition processes (see [74]). The
task is designed in a block-wise fashion, comprising four
Go and four NoGo blocks with a duration of 30 s each.
These two blocks are presented in an ABABABAB design.
In each block, a stream of 16 letters is presented (stimulus
presentation time: 175 ms; interstimulus interval: 1700 ms).
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hand via button press to each letter, but to withhold their
response when the letter ‘N’ is presented. While in the Go
blocks no ‘Ns’ are shown, 50% of the letters in the NoGo
blocks are ‘Ns’. RTs and errors are recorded, whereupon
the latter are classified into commission errors (false
alarms) and omission errors (missing reactions). The task
lasts for about 8 min.
Verbal fluency task
A verbal fluency task is used to investigate executive
functions. In the phonological condition (letters), partici-
pants have to name as many nouns as possible that
come to their mind with a previously defined first letter
for 30 s. In the semantic condition (category), partici-
pants have to name as many nouns as possible that
come to their mind out of a previously defined category
for 30 s. In the control condition (weekdays), participants
have to name the weekdays for 30 s. These three condi-
tions are performed alternately in a blockwise fashion, sep-
arated by 30-s resting segments during which participants
are instructed to sit still and relax. Each of the three task
conditions is conducted three times; that is, participants
perform nine task segments. Additionally, a 10-s baseline
period precedes the first task segment. The task lasts for
about 10 min.
Primary and secondary endpoints
As a primary outcome, the changes in core symptoms
will be assessed by the ADHS-SB (self-report) and the
FEA-AFB as well as WRI (third party evaluation). Vari-
ables of secondary outcome will include cognitive factors
(that is, attention, intelligence, response inhibition, and
working memory) and changes in specific EEG/ERP and
NIRS parameters (that is, relative and absolute power
and frequency ratios, concentration changes in O2Hb
and HHb), as well as achievement of self-regulation.
For the pre- and postevaluation, the independent vari-
able is the treatment (SCP, NIRS, or placebo feedback).
In addition, for the comparison of the neurophysio-
logical and cognitive data the health status (healthy and
ADHD participants) constitutes another independent
variable.
Risks and side effects
The medical risks of EEG and EMG recordings are few,
rare, and quickly remediable. For individuals who have
highly sensitive skin, there is the possibility of temporary
skin irritation caused by cleaning the scalp with abrasive
cleaning gel and the subsequent application of electrode
gel to improve the electrical conductivity between the
skin and electrode. No electrical current is applied; only
electrical output is recorded from the sensors. Addition-
ally, the EEG acquisition and neurofeedback equipmentused in this investigation are certified as medical devices
(class IIa. EU) for the use with human subjects.
Risks associated with EEG- or EMG-feedback treatment
are also few, rare, and quickly remediable. For individuals
who are highly sensitive or susceptible, neurofeedback
may precipitate a headache (muscle tension induced), hot
flash, or mild anxiety (performance induced). Potential
problems can be minimized and averted by obtaining an
appropriate medical history prior to treatment. Side effects
are typically mild, transient, and quickly remediable,
allowing participants to continue the treatment.
NIRS is an optical method for examining the oxygen
level of cortical tissue. Light from the near-infrared
spectrum (700–1000 nm wave length) can penetrate the
skull of an adult head and can be absorbed by two chromo-
phores (oxygenated hemoglobin or reduced hemoglobin).
As the two types of hemoglobin differ in the amount of
light they absorb, concentration changes of both types of
hemoglobin in the brain tissue can be derived, and from
this, information about the brain activity can be drawn
[31]. An advantage of this method, especially for ADHD
participants, is its relative insensitivity to movement arti-
facts. There are no medical risks associated with NIRS
recording; whereas for the neurofeedback aspect, side-
effects are expected to be similar to the ones observed for
EEG neurofeedback protocols (see above). All measure-
ments will be conducted in the presence of an experienced
research assistant.Statistics
Sample-size calculation
The basic problem with determining the number of
cases needed is that there are no comparable studies
about SCP training in adults and even fewer studies
about the influence of the blood flow regulation. For this
study, the planned sample size is based on a power cal-
culation of a meta-analysis by Arns et al. [75] that
showed a grand mean effect size of 0.81 for improve-
ments in inattention in children with ADHD by EEG
neurofeedback training as compared to passive or semi-
active (for example, EMG) placebo trainings. Assuming
a pre-defined α of 0.05, a power criterion of at least 80%,
and one-sided testing, such an effect size would indicate
a required sample size of n = 20 per treatment group.Statistical analysis
Electroencephalogram, near-infrared spectroscopy,
electromyogram and behavioral data
All dependent variables will be tested for effects within
and between groups by an analysis of variance (ANOVA)
(three groups x four assessment points). For the com-
parison of pretest-data between ADHD and healthy sub-
jects, t-tests and/or one-way ANOVAs will be applied. If
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tests will be used.
Neurophysiological predictors
To investigate neurophysiological predictors of treat-
ment outcome, target parameters of the baseline NIRS,
EEG, and peripheral physiology data assessments will be
analyzed in all treatment groups (SCP, NIRS, and EMG).
Specific to the NIRS assessment parameters, mean task-
related activation (changes in the concentration of O2Hb
and HHb) during the baseline assessment will be indi-
vidually calculated for both the 2-back condition of the
working memory (n-back) task and the NoGo condition
of the Go-NoGo paradigm. Specific to the EEG assess-
ment parameters, like mean relative theta and relative
beta power and theta/beta ratios will be calculated for
frontal and central ROIs during eyes open and eyes
closed resting state conditions. Additionally, P300 and
CNV amplitudes and latencies for these ROIs will be cal-
culated during neuropsychological assessments. The per-
ipheral data from heart rate, respiration, and SCL will be
used to assess the peripheral arousal during active (ERP
tasks) and resting (eyes open/eyes closed) conditions.
These parameters will then be used as independent vari-
ables in a regression analysis to predict treatment suc-
cess (as indicated by changes in psychometric scores in
the ADHD symptom scales).
Training-data
Session 1 will be discarded because it is assumed that par-
ticipants still have to habituate to the setting. NIRS, SCP
and EMG feedback data will be analyzed to determine:
1. If participants in treatment groups are able to learn
self-regulation of the trained parameter over the
course of treatment and at 6-month follow-up.
2. If the difference between activation and deactivation
changes throughout treatment.
3. Further, the participants will be divided into learners
and nonlearners of self-regulation for further analysis.
Slow cortical potential group
For each participant, mean differences between SCP am-
plitudes during both tasks (negativity/positivity) will be
calculated. The differences between SCP amplitude in
activation and deactivation will be analyzed separately
over the cause of treatment to assess the acquired self-
regulation abilities. This will be analyzed for feedback
and transfer conditions.
Electromyogram group
Data will be analyzed in the same manner as the SCP
data.Near-infrared spectroscopy group
Hemodynamic responses will be quantified for tasks (ac-
tivation/deactivation/rest), conditions (feedback/transfer)
and over the course of treatment. Differences between
hemodynamic response amplitudes in activation versus
deactivation (as well as rest) trials will be analyzed separ-
ately for each assessment point. Changes in the
hemodynamic responses for activation and deactivation
trials over time (as well as changes in the difference of
activation versus deactivation trials) will be analyzed and
computed for both feedback and transfer conditions.Discussion
This paper presents the protocol and design of a ran-
domized controlled trial with two types of neurofeed-
back (SCP and NIRS) and an active control (EMG
biofeedback) condition for adults with ADHD. This is
the first study to systematically investigate neurofeed-
back in adults with ADHD. It is also the first study to
compare SCP and NIRS feedback to an active control
condition on the one hand and to investigate this in an
adult ADHD population on the other hand.
If one or both feedback types are superior to the con-
trol condition, a first step will be made towards a new
acknowledged treatment option for adult ADHD.
This is not the “gold standard” design for treatment
studies, which is a placebo-controlled randomized
double blind design [76]. The problems with this approach
are widely discussed elsewhere [77,78]. Therefore, to allow
for all therapeutic aspects of neurofeedback therapy to
come into effect, such as a good patient-therapist relation-
ship, psychoeducation, and strengthening of self-efficacy
expectations, we decided to use an active control condi-
tion that was used in other studies before. The study de-
sign was based on a study protocol of a multicenter
treatment study with ADHD children [57]. The use of
EMG feedback as an active control condition is based on
the rationale that EMG feedback is not an “empty” treat-
ment, but will induce identical nonspecific (placebo) ef-
fects that will help to differentiate between specific effects
of the neurofeedback and nonspecific effects from the
above-mentioned aspects.Possible limitations
As this study is being conducted with adults, we did not
implement transfer exercises from the study on children
[57] in which the children performed homework in com-
bination with transfer trials in the lab. We also did not
include a token system in which good cooperation was
rewarded with stickers that the children were able to ex-
change for little presents or coupons. Whether this motiv-
ational aspect should have been implemented, remains
open.
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pects. First, there is a need for more research in the field
of adult ADHD and especially in the field of neurofeed-
back treatment for adult participants with ADHD.
ADHD changes its characteristics with maturation, and
therefore, findings from a childhood population have
only a limited impact on adult ADHD research. Second,
NIRS feedback is a new and potentially more time-
efficient type of self-regulation therapy. To date, an in-
vestigation and comparison of SCP and NIRS feedback
training to an active control has not been conducted;
therefore, we hope to gain valuable insights in effects and
differences of these types of treatment for ADHD in adults.
Trial status
The trial is ongoing.
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